IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

Phase 2CALMAPositive

AI Analysis

Summary

IGC Pharma is strengthening regulatory readiness as its Phase 2 CALMA Alzheimer's trial approaches enrollment closure with a Q4 topline readout expected.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Trial approaching enrollment closure with Q4 topline readout expected

Importance:6/10

Sentiment:

0.40

Alzheimer'sPhase 2Clinical TrialRegulatoryData Readout

Related Companies

$IGC

Read the original article

Published by yahoo_finance on August 11, 2026 12:30 PM

Read Original